

## Posaconazole Gastro-Resistant Tablets 100 mg

### Posaone

### पोसावन


**To be sold by retail on the prescription of Registered Medical Practitioner only**

### COMPOSITION

Each Gastro-Resistant Tablet contains:  
Posaconazole ..... 100 mg

### DRUG DESCRIPTION

Posaconazole is an azole antifungal agent available as gastro-resistant tablet for oral administration. Posaconazole is designated chemically as 4-[4-[4-[[[(3R,5R)-5-(2,4-difluorophenyl) tetrahydro-5H-1H-1,2,4-triazol-1-ylmethyl]-3-furanyl] methoxy] phenyl]-1-piperazinyl] phenyl]-2-[(1S,2S)-1-ethoxy-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one with an empirical formula of C<sub>27</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> and a molecular weight of 700.8. The chemical structure is:



Posaconazole is a white to off-white color powder. Posaconazole is soluble in dichloromethane and practically insoluble in water.

### DOSEAGE FORM AND STRENGTHS

Posaconazole is available as 100 mg gastro-resistant tablets.

### PHARMACODYNAMICS AND PHARMACOKINETICS

#### PHARMACODYNAMICS

Pharmaco-therapeutic group: Antimicrobials for systemic use, triazole derivatives, ATC code: J02A C04.

#### Mechanism of Action:

Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis.

#### Microbiology

Posaconazole has been shown *in vitro* to be active against the following microorganisms: *Aspergillus* species (*Aspergillus fumigatus*, *A. flavus*, *A. terreus*, *A. nidulans*, *A. niger*, *A. ustus*), *Candida* species (*Candida albicans*, *C. glabrata*, *C. Krusei*, *C. parapsilosis*, *C. tropicalis*, *C. dubliniensis*, *C. famata*, *C. inconspicua*, *C. lipolytica*, *C. norvegensis*, *C. pseudotropicalis*), *Coccidioides immitis*, *Fonsecaea pedrosoi*, and species of *Fusarium*, *Rhizomucor*, *Mucor*, and *Rhizopus*. The microbiological data suggest that posaconazole is active against *Rhizomucor*, *Mucor*, and *Rhizopus*; however the clinical data are currently too limited to assess the efficacy of posaconazole against these causative agents.

#### Resistance

Clinical isolates with decreased susceptibility to posaconazole have been identified. The principle mechanism of resistance is the acquisition of substitutions in the target protein, CYP51.

#### Epidemiological Cut-off (ECOFF) values for *Aspergillus* spp.

The ECOFF values for posaconazole, which distinguish the wild type population from isolates with acquired resistance, have been determined by EUCAST methodology.

EUCAST ECOFF values:

- *Aspergillus flavus*: 0.5 mg/L
- *Aspergillus fumigatus*: 0.25 mg/L
- *Aspergillus nidulans*: 0.5 mg/L
- *Aspergillus niger*: 0.5 mg/L
- *Aspergillus terreus*: 0.25 mg/L

There are currently insufficient data to set clinical breakpoints for *Aspergillus* spp. ECOFF values do not equate to clinical breakpoints.

#### Breakpoints

EUCAST MIC breakpoints for posaconazole [susceptible (S); resistant (R)]:

- *Candida albicans*: S ≤0.06 mg/L, R >0.06 mg/L
- *Candida tropicalis*: S ≤0.06 mg/L, R >0.06 mg/L
- *Candida parapsilosis*: S ≤0.06 mg/L, R >0.06 mg/L

There are currently insufficient data to set clinical breakpoints for other *Candida* species.

#### Combination with other antifungal agents

The use of combination antifungal therapies should not decrease the efficacy of either posaconazole or the other therapies; however, there is currently no clinical evidence that combination therapy will provide an added benefit.

#### Pharmacokinetics

##### Pharmacokinetic / Pharmacodynamic relationships

A correlation between total medicinal product exposure divided by MIC (AUC/MIC) and clinical outcome was observed. The critical ratio for subjects with *Aspergillus* infections was ~200. It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with *Aspergillus*.

#### Absorption

Posaconazole tablets are absorbed with a median T<sub>max</sub> of 4 to 5 hours and exhibits dose proportional pharmacokinetics after single and multiple dosing up to 300 mg.

Following a single dose administration of 300 mg posaconazole tablets after a high fat meal to healthy volunteers, the AUC<sub>0-72</sub> hours and C<sub>max</sub> were higher compared to administration under fasted condition (51 % and 16 % for AUC<sub>0-72</sub> hours and C<sub>max</sub> respectively).

Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients. The reason for this time-dependency is not completely understood.

#### Distribution

Posaconazole, after administration of the tablet, has a mean apparent volume of distribution of 394 L (42 %), ranging between 294-583 L among the studies in healthy volunteers.

Posaconazole is highly protein bound (> 98 %), predominantly to serum albumin.

#### Biotransformation

Posaconazole does not have any major circulating metabolites and its concentrations are unlikely to be altered by inhibitors of CYP450 enzymes. Of the circulating metabolites, the majority are glucuronide conjugates of posaconazole with only minor amounts of oxidative (CYP450 mediated) metabolites observed. The excreted metabolites in urine and faeces account for approximately 17 % of the administered radiolabelled dose.

#### Elimination

Posaconazole after administration of the tablets, is slowly eliminated with a mean half-life (t<sub>1/2</sub>) of 29 hours (range 26 to 31 hours) and a mean apparent clearance ranging from 7.5 to 11 L/hr. After administration of <sup>14</sup>C-positaconazole, radioactivity was predominantly recovered in the faeces (77 % of the radiolabelled dose) with the major component being parent compound (66 % of the radiolabelled dose). Renal clearance is a minor elimination pathway, with 14 % of the radiolabelled dose excreted in urine (< 0.2 % of the radiolabelled dose is parent compound). Steady-state plasma concentrations are attained by Day 6 at the 300 mg dose (once daily after twice daily loading dose at Day 1).

#### INDICATIONS

Posaconazole Gastro-Resistant tablets are indicated for prophylaxis of invasive *Aspergillus* and *Candida* infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Posaconazole Gastro-Resistant tablets are indicated in patients 13 years of age and older.

#### DOSE AND METHOD OF ADMINISTRATION

Treatment should be initiated by a physician experienced in the management of fungal infections or in the supportive care in the high risk patients for which posaconazole is indicated as prophylaxis.

Dosage and Administration Instructions for Posaconazole gastro-resistant Tablets

Dosage:

Indication	Dose and Duration of Therapy
Refractory invasive fungal infections (IFI)/patients with IFI intolerant to 1st line therapy	Loading dose of 300 mg (three 100 mg tablets) twice a day on the first day, then 300 mg (three 100 mg tablets) once a day thereafter. Each dose may be taken without regard to food intake. Duration of therapy should be based on the severity of the underlying disease, recovery from immunosuppression, and clinical response.
Prophylaxis of invasive fungal infections	Loading dose of 300 mg (three 100 mg tablets) twice a day on the first day, then 300 mg (three 100 mg tablets) once a day thereafter. Each dose may be taken without regard to food intake. Duration of therapy is based on recovery from neutropenia or immunosuppression. For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with Posaconazole should start several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per mm <sup>3</sup> .

#### USE IN SPECIAL POPULATIONS

##### Renal impairment

An effect of renal impairment on the pharmacokinetics of posaconazole is not expected and no dose adjustment is recommended.

##### Hepatic impairment

Limited data on the effect of hepatic impairment (including Child-Pugh C classification of chronic liver disease) on the pharmacokinetics of posaconazole demonstrate an increase in plasma exposure compared to subjects with normal hepatic function, but do not suggest that dose adjustment is necessary. It is recommended to exercise caution due to the potential for higher plasma exposure.

##### Paediatric population

The safety and efficacy of Posaconazole in children aged below 18 years have not been established no recommendation on a posology can be made.

##### Geriatric use

The pharmacokinetics of posaconazole tablets are comparable in young and elderly patients. No overall differences in safety were observed between the geriatric patients and younger patients; therefore, no dosage adjustment is recommended for geriatric patients.

##### Pregnancy

There is insufficient information on the use of posaconazole in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.

Women of childbearing potential have to use effective contraception during treatment. Posaconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.

##### Breast-feeding

Posaconazole is excreted into the milk of lactating rats. The excretion of posaconazole in human breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with posaconazole.

##### Fertility

Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (3.4 times the 300-mg tablet based on steady-state plasma concentrations in patients) or female rats at a dose up to 45 mg/kg (2.6 times the 300-mg tablet based on steady-state plasma concentrations in patients). There is no clinical experience assessing the impact of posaconazole on fertility in humans.

##### Gender

The pharmacokinetics of posaconazole are comparable in men and women. No adjustment in the dosage of Posaconazole is necessary based on gender.

##### Race

The pharmacokinetic profile of posaconazole is not significantly affected by race. No adjustment in the dosage of Posaconazole is necessary based on race.

##### Weight

Pharmacokinetic modeling suggests that patients weighing greater than 120 kg may have lower posaconazole plasma drug exposure. It is, therefore, suggested to closely monitor for breakthrough fungal infections

#### CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients used in formulation

Co-administration with ergot alkaloids

Co-administration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes.

Co-administration with the HMG-CoA reductase inhibitors simvastatin, lovastatin and atorvastatin

#### WARNINGS AND PRECAUTIONS

##### Hypersensitivity

There is no information regarding cross-sensitivity between posaconazole and other azole antifungal agents. Caution should be used when prescribing Posaconazole to patients with hypersensitivity to other azoles.

##### Hepatic toxicity

Hepatic reactions (e.g. mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin and/or clinical hepatitis) have been reported during treatment with posaconazole. Elevated liver function tests were generally reversible on discontinuation of therapy and in some instances these tests normalised without interruption of therapy. Rarely, more severe hepatic reactions with fatal outcomes have been reported.

Posaconazole should be used with caution in patients with hepatic impairment due to limited clinical experience and the possibility that posaconazole plasma levels may be higher in these patients.

##### Monitoring of hepatic function

Liver function tests should be evaluated at the start of and during the course of posaconazole therapy. Patients who develop abnormal liver function tests during Posaconazole therapy must be routinely monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of Posaconazole should be considered if clinical signs and symptoms are consistent with development of liver disease.

##### QTc prolongation

Some azoles have been associated with prolongation of the QTc interval. Posaconazole must not be administered with medicinal products that are substrates for CYP3A4 and are known to prolong the QTc interval. Posaconazole should be administered with caution to patients with pro-arrhythmic conditions such as:

- Congenital or acquired QTc prolongation
- Cardiomyopathy, especially in the presence of cardiac failure
- Sinus bradycardia
- Existing symptomatic arrhythmias
- Concomitant use with medicinal products known to prolong the QTc interval.

Electrolyte disturbances, especially those involving potassium, magnesium or calcium levels, should be monitored and corrected as necessary before and during posaconazole therapy.

##### Drug Interactions

Posaconazole is an inhibitor of CYP3A4 and should only be used under specific circumstances during treatment with other medicinal products that are metabolised by CYP3A4.

##### Midazolam and other benzodiazepines

Due to the risk of prolonged sedation and possible respiratory depression co-administration of posaconazole with any benzodiazepines metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam) should only be considered if clearly necessary. Dose adjustment of benzodiazepines metabolised by CYP3A4 should be considered.

##### Vincristine Toxicity

Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with neurotoxicity and other serious adverse reactions, including seizures, peripheral neuropathy, syndrome of inappropriate antidiuretic hormone secretion, and paralytic ileus. Reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.

##### Rifamycin antibacterials (rifampicin, rifabutin), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone), and efavirenz

Posaconazole concentrations may be significantly lowered in combination; therefore, concomitant use with posaconazole should be avoided unless the benefit to the patient outweighs the risk.

##### Plasma exposure

Posaconazole plasma concentrations following administration of posaconazole tablets are generally higher than those obtained with posaconazole oral suspension. Posaconazole plasma concentrations following administration of posaconazole tablets may increase over time in some patients. Safety data at higher exposure levels achieved with posaconazole tablets are at present limited.

##### Gastrointestinal dysfunction

There are limited pharmacokinetic data in patients with severe gastrointestinal dysfunction (such as severe diarrhoea). Patients who have severe diarrhoea or vomiting should be monitored closely for breakthrough fungal infections.

#### DRUG INTERACTIONS

##### Effects of other medicinal products on posaconazole

Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for p-glycoprotein (P-gp) efflux *in vitro*. Therefore, inhibitors (e.g. verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, etc.) or inducers (e.g. rifampicin, rifabutin, certain anticonvulsants, etc.) of these clearance pathways may increase or decrease posaconazole plasma concentrations, respectively.

##### Rifabutin

Concomitant use of posaconazole and rifabutin and similar inducers (e.g. rifampicin) should be avoided unless the benefit to the patient outweighs the risk. See also below regarding the effect of posaconazole on rifabutin plasma levels.

##### Efavirenz

Concomitant use of posaconazole and efavirenz should be avoided unless the benefit to the patient outweighs the risk.

##### Fosamprenavir

Combining fosamprenavir with posaconazole may lead to decreased posaconazole plasma concentrations. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended. The effect of posaconazole on fosamprenavir levels when fosamprenavir is given with ritonavir is unknown.

##### Phenytoin

Concomitant use of posaconazole and phenytoin and similar inducers (e.g. carbamazepine, phenobarbital, primidone) should be avoided unless the benefit to the patient outweighs the risk.

##### H2-receptor antagonists and proton pump inhibitors

No clinically relevant effects were observed when posaconazole tablets are concomitantly used with antacids, H2-receptor antagonists and proton pump inhibitors. No dosage adjustment of posaconazole tablets is required when posaconazole tablets are concomitantly used with antacids, H2-receptor antagonists and proton pump inhibitors.

##### Effects of posaconazole on other medicinal products

Posaconazole is a potent inhibitor of CYP3A4. Co-administration of posaconazole with CYP3A4 substrates may result in large increases in exposure to CYP3A4 substrates as exemplified by the effects on tacrolimus, sirolimus, atazanavir and midazolam below. Caution is advised during co-administration of posaconazole with CYP3A4 substrates administered intravenously and the dose of the CYP3A4 substrate may need to be reduced. If posaconazole is used concomitantly with CYP3A4 substrates that are administered orally, and for which an increase in plasma concentrations may be associated with unacceptable adverse reactions, plasma concentrations of the CYP3A4 substrate and/or adverse reactions should be closely monitored and the dose adjusted as needed. The effect of co-administration with posaconazole on plasma levels of CYP3A4 substrates may also be variable within a patient.

##### Terfenadine, astemizole, cisapride, pimozide, halofantrine and quinidine (CYP3A4 substrates)

Co-administration of posaconazole and terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine is contraindicated. Co-administration may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of Torsades de pointes.

##### Ergot alkaloids

Posaconazole may increase the plasma concentration of ergot alkaloids (ergotamine and dihydroergotamine), which may lead to ergotism. Co-administration of posaconazole and ergot alkaloids is contraindicated.

##### HMG-CoA reductase inhibitors metabolised through CYP3A4 (e.g. simvastatin, lovastatin, and atorvastatin)

Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4. Treatment with these HMG-CoA reductase inhibitors should be discontinued during treatment with posaconazole as increased levels have been associated with rhabdomyolysis.

##### Vinca alkaloids

Most of the vinca alkaloids (e.g., vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions. Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.

##### Rifabutin

Concomitant use of posaconazole and rifabutin should be avoided unless the benefit to the patient outweighs the risk (see also above regarding the effect of rifabutin on plasma levels of posaconazole). If these medicinal products are co-administered, careful monitoring of full blood counts and adverse reactions related to increased rifabutin levels (e.g. uveitis) is recommended.

##### Sirolimus

The effect of posaconazole on sirolimus in patients is unknown, but is expected to be variable due to the variable posaconazole exposure in patients. Co-administration of posaconazole with sirolimus is not recommended and should be avoided whenever possible. If it is considered that co-administration is unavoidable, then it is recommended that the dose of sirolimus should be greatly reduced at the time of initiation of posaconazole therapy and that there should be very frequent monitoring of trough concentrations of sirolimus in whole blood. Sirolimus concentrations should be measured upon initiation, during co-administration, and at discontinuation of posaconazole treatment, with sirolimus doses adjusted accordingly. It should be noted that the relationship between sirolimus trough concentration and AUC is changed during co-administration with posaconazole. As a result, sirolimus trough concentrations that fall within the usual therapeutic range may result in sub-therapeutic levels. Therefore, trough concentrations that fall in the upper part of the usual therapeutic range should be targeted and careful attention should be paid to clinical signs and symptoms, laboratory parameters and tissue biopsies.

##### Ciclosporin

Cases of elevated ciclosporin levels resulting in serious adverse reactions, including nephrotoxicity and one fatal case of leukoencephalopathy, were reported. When initiating treatment with posaconazole in patients already receiving ciclosporin, the dose of ciclosporin should be reduced (e.g. to about three quarters of the current dose). Thereafter blood levels of ciclosporin should be monitored carefully during co-administration, and upon discontinuation of posaconazole treatment, the dose of ciclosporin should be adjusted as necessary.

##### Tacrolimus

Clinically significant interactions resulting in hospitalisation and/or posaconazole discontinuation were reported in clinical efficacy studies. When initiating posaconazole treatment in patients already receiving tacrolimus, the dose of tacrolimus should be reduced (e.g. to about one third of the current dose). Thereafter blood levels of tacrolimus should be monitored carefully during co-administration, and upon discontinuation of posaconazole, and the dose of tacrolimus should be adjusted as necessary.

##### HIV Protease inhibitors

As HIV protease inhibitors are CYP3A4 substrates, it is expected that posaconazole will increase plasma levels of these antiretroviral agents. The addition of posaconazole to therapy with atazanavir or with atazanavir plus ritonavir was associated with increases in plasma bilirubin levels. Frequent monitoring for adverse reactions and toxicity related to antiretroviral agents that are substrates of CYP3A4 is recommended during co-administration with posaconazole.

##### Midazolam and other benzodiazepines metabolised by CYP3A4

Due to the risk of prolonged sedation it is recommended that dose adjustments should be considered when posaconazole is administered concomitantly with any benzodiazepine that is metabolised by CYP3A4 (e.g. midazolam, triazolam, alprazolam).

##### Calcium channel blockers metabolised through CYP3A4 (e.g. diltiazem, verapamil, nifedipine, nisoldipine)

Frequent monitoring for adverse reactions and toxicity related to calcium channel blockers is recommended during co-administration with posaconazole. Dose adjustment of calcium channel blockers may be required.

##### Digoxin

Administration of other azoles has been associated with increases in digoxin levels. Therefore, posaconazole may increase plasma concentration of digoxin and digoxin levels need to be monitored when initiating or discontinuing posaconazole treatment.

##### Sulfonlureas

Glucose concentrations decreased in some healthy volunteers when glipizide was co-administered with posaconazole. Monitoring of glucose concentrations is recommended in diabetic patients.

#### UNDESIRABLE EFFECTS

Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); not known.

Table: Adverse reactions by body system and frequency<sup>†</sup>

Body system	Adverse reactions
<b>Blood and lymphatic system disorders</b>	
Common:	neutropenia
Uncommon:	thrombocytopenia, leukopenia, anaemia, eosinophilia, lymphadenopathy, splenic infarction
Rare:	haemolytic uraemic syndrome, thrombotic thrombocytopenic purpura, pancytopenia, coagulopathy, haemorrhage
<b>Immune system disorders</b>	
Uncommon:	allergic reaction
Rare:	hypersensitivity reaction
<b>Endocrine disorders</b>	
Rare:	adrenal insufficiency, blood gonadotropin decreased
<b>Metabolism and nutrition disorders</b>	
Common:	electrolyte imbalance, anorexia, decreased appetite, hypokalaemia, hypomagnesaemia
Uncommon:	hyperglycaemia, hypoglycaemia
<b>Psychiatric disorders</b>	
Uncommon:	abnormal dreams, confusional state, sleep disorder
Rare:	psychotic disorder, depression
<b>Nervous system disorders</b>	
Common:	paresthesia, dizziness, somnolence, headache, dysgeusia
Uncommon:	convulsions, neuropathy, hypoaesthesia, tremor, aphasia, insomnia
Rare:	cerebrovascular accident, encephalopathy, peripheral neuropathy, syncope
<b>Eye disorders</b>	
Uncommon:	blurred vision, photophobia, visual acuity reduced
Rare:	diplopia, scotoma
<b>Ear and labyrinth disorder</b>	
Rare:	hearing impairment
<b>Cardiac disorders</b>	
Uncommon:	long QT syndrome <sup>‡</sup> , electrocardiogram abnormal <sup>‡</sup> , palpitations, bradycardia, supra-ventricular extrasystoles, tachycardia</